PFE - Eli Lilly Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors | Benzinga
The race for new drugs to fight obesity and associated diabetes and cardiovascular diseases heated up on Monday after positive results from trials by Zealand Pharma were published, pushing the Danish company’s shares 30% higher.
Zealand Pharma’s survodutide drug showed positive results in 83% of patients in Phase 2 trials being tested for a liver disease caused by excess fat cells called MASH, the company announced on Monday.
“Survodutide has demonstrated efficacy in people with obesity, and statistically significant results in MASH suggest the potential to lead to clinically meaningful benefits across the cardiovascular, renal, and metabolic spectrum,” the announcement said.
The blockbuster impact of drugs such as Novo Nordisk‘s (NYSE:NVO) Ozempic and Eli Lilly And Company‘s (NYSE:LLY) Mounjaro, have driven dozens of companies to research and develop rival weight-loss treatments and further announcements of breakthroughs in the fast-developing market are ...